Two examples of why BIEL will never succeed.
1)They are not paying their employment taxes, behind on payments to employees and the SEC settlement. BTW, you don't "settle" unless you are guilty.
Payroll Taxes $ 475,063
Estimated Penalties & Interest 246,946
SEC Settlement Agreement 191,640
Employee Compensation 100,795

Total accrued expenses $ 1,029,385



2)During the first second quarter of 2018, the Company entered into a convertible note agreement with
James Eason, receiving financing of $135,000, with an interest rate of 8% per annum and convertible
at a rate of $.0003 per share. This loan and related interest was converted into 629,856,000 shares of
common stock in July 2020

If you do the math, Eason, at the current share price has stock valued at $755,827.72, a "profit" of $630k. Although he cannot sell his shares because the stock trades so thin, he could reasonably be willing to sell all the way down to $0.004, still seeing a 33% ROI at the lowest point. This is just ONE of the many that are holding this quantity of shares. This stock is more likely to disappear than to ever see $0.003 again.

Spot on. Whelan is a CLOWN. Whatever happened to the CE mark that was supposed to be renewed by the end of July? Just more BS from Bozo.

Can BIEL ship product?
One, we just are looking for ONE good, ok, one average decision from Whealan.
What will they do differently with FDA clearance with Recovery RX.
Are we ever going to see a professional update or news release?
Real public companies have a BOD to prevent exactly what Whealan continues to do.
Do you really believe Recovery RX will be any different?

I would suspect that the first, second, third....series of convertibles were at better terms for BIEL. As Whealan makes poor decision after poor decision, the company continues to flounder, the cost of capital rises.

At this point, it is common knowledge he is incapable of commercializing Actipatch/RX. Who would loan money knowing that he is going to continue to be involved? Someone who is getting such a high "premium" they feel that can't lose. Add this to the long list of Whealanisms (SNAFU). The terms have to be so good that you have to be able to be willing to take the stock down to sell that number of shares.

Agreed, noun, verb.....

I call BS.

"The Company is in discussions with two major organizations to rollout the RecoveryRx product in the US". # 1, ROLLOUT is not a word, so we know Whealan wrote this release without proofreading. #2-When did they start, why does it not say "we have been in negotiations ... for the past ... months".

"we are working to list the product with three major drug wholesalers". WORKING? Does that mean you left a VM or sent an email? They are "working" to get the product in Walmart, one meeting.

"ActiPatch® is already FDA-cleared for adjunctive treatment of pain from knee osteoarthritis (25 million) and plantar fasciitis (2 million annually)". 1st qtr sales of $140K. total.

"The ISO certification, along with the technical file review comprise the two parts required to meet current CE mark requirements". ANOTHER TYPO. I seriously doubt an ISO cert. is required for a CE mark. Certainly a GMP cert. is required, but doubtful an ISO cert. is. If it is, is this another reason why they do not have a CE mark? If so, is everything shipped to this point in violation of the protocol of the CE requirements and subject to recall?

"The Walmart meeting went really well. At this point,we have been asked by the buyer to show a couple things of interest". ANOTHER TYPO. I guarantee this is the first time in history a public company is reporting a SALES CALL to a major retailer. I would guess if the buyer sees this, they would no longer communicate with BIEL.

B. Braun is supposed to be using SIX Actipatches per knee replacement. Whealan told us sales would show up 1st qtr. 2019, they did, $140K TOTAL SALES WORLDWIDE FOR THE COMPANY. This is down 75% from when they received FDA clearance for the knee and the foot. They cannot ship product because of the lack of a CE mark. It is difficult to believe B Braun is chomping at the bit to market in the US after Whealan failed to deliver product in the UK. However, if they are the chosen partner, the announcement could come any day. Does anyone wish to wager that they do not announce a partner in the next 60 days????

We will be sitting right where we are a year from now. Just as we are two plus years after receiving approval for the knee and foot, no sales in TWO YEARS!! He has no plan, he will start talking about a partnership with a large global company., "they have the money to market the product, Large companies move slowly........". He has said all of this before. If they do not know him by reputation, it will not take them as long as it took Bayer, KT Tape and others to run away.

THIS IS WHY THE STOCK DISAPPOINTED YESTERDAY. WHEALAN HAS BEEN EXPOSED.

Oh, like Boots and CVS? Whealan didn't like the largest pharmacy in the UK. Whealan didn't like the largest pharmacy in the US. Do you think the stock would be at .000 if he were in Boots and CVS?

DOES WHEALAN HAVE A BUSINESS PLAN?

We will see if he has thought this out further than tomorrow. If so, he would have begun or completed the following:

-All sales training materials would be completed along with the responsibility assigned for each segment of training.
-Price point evaluation based on data.
-New packaging would be completed.
-The device manufacturer would be aware of the possibility of winning the new business and a timeline for the expected pipeline quantities agreed upon.
-Vetted potential sales forces, contract/partners with that have a presence in the hospital/surgical setting. The selected group/groups should have the ability to readily communicate with the decision makers and/or influencers in the surgical arena.
-At the least, a general discussion between parties regarding areas of coverage and compensation.
-An understanding of a sales force training schedule for the product.

If we do not hear of an agreement in the next 60 days, add this to the list of his failures. If it takes more than 90 days, they haven't started it yet. I'm betting 90+ days.

It will be interesting to see if B. Braun US is at all interested in the product after their experience dealing with Whealan in the UK. Was their experience with him so bad they want nothing to do with a potentially disruptive technology? We know they are not selling in the UK. 1st qtr. told us that. What we hear, or don't hear from them, will speak volumes about his reputation.

DOES WHEALAN HAVE A BUSINESS PLAN?

We will see if he has thought this out further than tomorrow. If so, he would have begun or completed the following:

-All sales training materials would be completed along with the responsibility assigned for each segment of training.
-Price point evaluation based on data.
-New packaging would be completed.
-The device manufacturer would be aware of the possibility of winning the new business and a timeline for the expected pipeline quantities agreed upon.
-Vetted potential sales forces, contract/partners with that have a presence in the hospital/surgical setting. The selected group/groups should have the ability to readily communicate with the decision makers and/or influencers in the surgical arena.
-At the least, a general discussion between parties regarding areas of coverage and compensation.
-An understanding of a sales force training schedule for the product.

If we do not hear of an agreement in the next 30 days, add this to the list of his failures. If it takes more than 90 days, they haven't started it yet. I'm betting 90+ days.

It will be interesting to see if B. Braun US is at all interested in the product after their experience dealing with Whealan in the UK. Is his reputation so bad they want nothing to do with a potentially disruptive technology? What we hear, or don't hear from them, will speak volumes about his reputation.

Whealan, 100% responsible for this debacle. Try to name another .000 stock that gets FDA clearance on a pain device to combat opioid abuse and goes up .0002. Everyone knows who is running the ship and they want nothing to do with him.

HE HAS TO GO!!!

There is such a large downward bias from shares issued in convertible notes. Imagine there are 1,000,000,000 shares that were converted from a "loan" at .0002-.0003. After the fact, the stock drops from .002 to .0005. You are now aware they have no CE mark, cannot ship product. You see quarter sales a fraction of what they were two years ago. You are reading the MundiPharma wants their money back. You are hearing the CVS deal is dead. You have seen them pulled from Boots. In spite of all of this, the stock moves to .0015. You have the chance to wipe your hands of Whealan, with a nice profit. That is a gift, they accepted the gift. Those are the 200,000,000 shares that were sold today. However, there are many more shares where those came from.


If there is a next time, take the gift.

That is how you trade a company run by a FOOL

The CEO is a clown. He has had FDA clearance on the knee and foot for two years. In this period, sales have DECLINED 75%. He has had a SEC judgment against him and his Daughter. If not for his ineptness and/or questionable ethics, this stock would be of multiple of where it is today, without today's news.

It's the Whealan effect. If he gets out of the way, this stock soars. If he sticks around, a year from now you will all be wondering why three more large companies told him to go to hell. Those who have been around for a few years will know the answer.

Invest only what you are willing to lose.

Marketing 101, you need cash. Let me guess, we will partner with a large company and they will provide the marketing. Think Kt Tape, Bayer....

If BIEL in fact has approval, obviously good news. However, it is tempered by the fact that Whealan is still steering the ship. If they get approval, it will move from the pathetic base he has created at .0007. If he wasn't as inept as he is, we would be moving from .0025-.0030, minimum. If he had not have blown the Boots, Kt Tape, Bayer and CVS deals, does anyone in their right mind believe we would be sitting at .0007?

The stock will not get the previous level of bounce because of the common knowledge he did not have the capacity to commercialize the Actipatch at the retail level. He certainly does not have the ability to do so in a hospital setting. Is there a partner who could do so? Undeniably, YES!! However, Whealan cannot make deals, in two years the sales of Recovery RX will mirror those of Actipatch if Whealan is still around.

Short story, realize you are dealing with a fool. Hope for the bounce, take profits, wait for him to stumble, buy back shares. Remember, the patent expires in 2023, you have a couple of years to trade his foolishness.

I do not see "Double blinded" referenced in either release.

CVS and Walmart are two different markets, two different sets of customers. When you choose to go to one or the other, you have made a decision based on reputation, brand, cost. On average, you will pay significantly more at CVS, typically have an option of a higher end product selection, therefore you have made the choice to be willing to pay a higher price. Customers at Walmart are far more cost-conscious than they are at CVS. I would argue that CVS is a much better platform than Walmart for the Actipatch. Although Walmart has exponentially more customers walk through the doors, CVS has as many, perhaps more customers, willing to pay the price point of the Actipatch. It would be great to see the Actipatch in Walmart, however, I would guess sales would be mediocre, at best.

I am sure Whealan has analyzed this and made an informed decision, .......not a chance in hell.

He doesn't have a plan for Tuesday, much less, next week.

That is certainly the narrative being pushed by Whealan, "anybody's fault but mine".

There are constant regulatory changes. The agencies provide notice and timeline for each and every change. Whealan, or whoever has regulatory responsibility was/is negligent, pure and simple.

The fact that Whealan suggested they lost the CE mark due to changes in the regulatory requirements is not true. If Whealan is not truthful in this instance, how can anything he says be trusted?

BIel most certainly needs a CE mark for Australia.

I wonder if the discussions include details of when BIEL might be able to actually supply product to sell.

Whealan's marketing plan to increase sales:

"Buy an Actipatch, receive TWO band-aids at no additional cost!!!"

Offer only valid in countries that do not require a CE mark.

When Whealan blows up the Mundipharma deal, should he be removed?

When Whealan blows up the Mundipharma deal, should he be removed?

How many sales reps does B. Braun have? They have been "selling" for a year. Whealan told us we would see results 1st quarter 2019. We did, $140K TOTAL sales.

Whealan has been really stupid for at least two years.....

HURRY, before the stock drops 25%. Oops, too late

That is just the tip of the iceberg. You will never see a more poorly run company, impossible. The technology is legitimate, the management is a trainwreck. Put in a buy at .0002 or .0003 and hope something happens to Whealan..... if so, the stock doubles overnight.

Very interesting. Please follow provided link, enter Actipatch in search, click on product.

OUT OF STOCK!!!

IF WHEALAN BLOWS UP THE MUNDIPHARMA DEAL, SHOULD BE BE FORCED TO RESIGN?

I have asked this question numerous times without a response.

IF WHEALAN BLOWS UP THE MUNDIPHARMA DEAL, SHOULD HE BE FORCED TO RESIGN?

A very simple question.

Incredible, no doubt. Incredible that sales have dropped 75%, share price has dropped 80%, two years after FDA clearance.

There is no rational defense of Whealan, NONE.

Whealan made a mess in the UK, then the US, next up Australia. According to his timeline, BIEL cannot ship product to Mundipharma until at least end of July.

Will Mundipharma realize what a clown this guy is and pull out? Why train 300 sales people when there is no product to sell? Someone's head is rolling at Mudipharma for getting involved with a company that cannot ship the promised product.

Where we could be without Whealan

Boots- BIEL annual sales were over $2million before Whealan blew up Boots. We can reasonably assume it would be in all 2485 Boots, based on being the "no. 1 item in the pain category". They could then have parlayed into Walgreens (owns Boots), 6400 stores. He told us the taking the product to prescription only in the UK was the best move, two years later, zero sales.

Scholls- A deal with Scholls puts us in every retailer in the US, Walmart, CVS, Walgreens, Rite Aid...., all small pharmacies, easily 30,000 potential stores. It is difficult to choose one of Whealan's blunders as the largest, but this has to be close.

KT Tape- they are probably in as many stores, if not more, than Scholls. This would be, conservatively, another 30,000 stores.

CVS- largest pharmacy in the US. Again, if we believe Whealan that the sales were very good, they would certainly continue the test and look to full store distribution, 9000 stores.

THIS IS OVER 75,000 STORES WHEALAN HAD A VERY REAL OPPORTUNITY TO ENTER. If he would have pulled half of these stores in, he could have raised more than enough money for a first class advertising campaign. We have all seen what Shaq advertising did to Icy Hot.

Where are we? Nowhere, zero. He has blown this all up. We have no distribution in the USA. Instead of having product in 70,000 stores, Whealan is touting a MEETING at Walmart. A MEETING!!!!!! We have sales of $140k in a quarter which equals $2.00/store of the 70,000+ potential he blew up. That is a pack of gum per store, per quarter!!

We have no CE mark to ship to Mundipharma.

The most worrisome if the reputation of BIEL. These companies will not come back and deal with BIEL. He is presenting a pie in the sky "Mudipharma is HUGE" even though he cannot ship product.

I have been guilty of not giving Whealan credit for getting the product to $2million+ sales. This is no small accomplishment and he deserves credit. However, from the time he lost Boots to now, he could not have possibly performed any worse.

CLASS ACTION

In 17+ years, Whealan has spent $30-35 million of investor's money for quarterly sales of $140k.

THAT IS PATHETIC!!!!!

Whealan must go!!!

Who cares if Protex is pissed? We want new management that can take advantage of the technology that Whealan has been unable to commercialize.
Two years, sales decline of 75%.
If he cannot commercialize the knee and foot, what makes you think he can capitalize Allay, full body?

I will ask again.

IF WHEALAN BLOWS THE MUNDIPHARMA DEAL, SHOULD BE KICKED OUT?

WE FOUND THE SOFT SPOT. We need to start a Go Fund Me page to rid BIEL from the Whealan destruction.

So we have 5 billion dollar companies resulting in quarterly sales of $140K.

Maybe we need to start finding trillion dollar companies......

Let us not forget Whealan told us the B Braun sales would start showing up in late 2018, early 2019. I guess they were included in the $140,000 (this number is not in thousands) first qtr. sales.

It's OK that Whealan allowing the CE mark to lapse because "it only amounts to $43k in profit".

That is so far from reality, we can hear Whealan saying that himself.

We will probably see that in the next "news" release.